Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and ImmunityBio, Inc.

Biotech Giants' SG&A Trends: A Decade in Review

__timestampCytokinetics, IncorporatedImmunityBio, Inc.
Wednesday, January 1, 2014172680004326000
Thursday, January 1, 201519667000226206000
Friday, January 1, 20162782300094391000
Sunday, January 1, 20173646800053821000
Monday, January 1, 20183128200035463000
Tuesday, January 1, 20193961000046456000
Wednesday, January 1, 20205282000071318000
Friday, January 1, 202196803000135256000
Saturday, January 1, 2022177977000102708000
Sunday, January 1, 2023173612000129620000
Loading chart...

Igniting the spark of knowledge

A Decade of SG&A Trends: Cytokinetics vs. ImmunityBio

In the ever-evolving biotech industry, operational costs are a critical factor in determining a company's financial health. Over the past decade, Cytokinetics, Incorporated and ImmunityBio, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Cytokinetics saw a staggering 900% increase in SG&A expenses, peaking in 2022. Meanwhile, ImmunityBio's expenses fluctuated, with a notable spike in 2015, reaching over 50 times their 2014 expenses. By 2023, both companies had aligned their SG&A costs, reflecting strategic shifts in their operational focus. This analysis provides a window into how these biotech giants manage their resources amidst industry challenges, offering insights into their strategic priorities and financial resilience.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025